妊娠对炎症性肠病中英夫利西单抗与阿达木单抗药代动力学的影响
前瞻性纳入卡尔加里大学炎症性肠病妊娠门诊25名维持使用英夫利西单抗或阿达木单抗的女性,每三个月进行血清生物样本库检测。调整白蛋白、BMI和CRP后,英夫利西单抗谷浓度每三个月增加4.2 μg/mL(P=0.02),阿达木单抗药物水平保持稳定(P>0.05)。作者认为妊娠中期进行治疗药物监测可能有助于指导妊娠晚期给药。
要点
- 英夫利西单抗谷浓度在妊娠期间升高,每三个月增加4.2 μg/mL(P=0.02)。
- 调整白蛋白、BMI和CRP后,阿达木单抗药物水平在妊娠期间保持稳定(P>0.05)。
- 作者认为妊娠中期进行治疗药物监测可能有助于指导妊娠晚期给药。
核心结论
- 调整白蛋白、BMI和CRP后,英夫利西单抗水平在妊娠期间升高,而阿达木单抗水平保持稳定。
- 作者认为妊娠中期进行治疗药物监测可能有助于指导妊娠晚期给药。
研究设计与样本
- 前瞻性研究,来自卡尔加里大学炎症性肠病妊娠门诊,纳入25名维持使用英夫利西单抗或阿达木单抗的女性,每三个月进行血清生物样本库检测。
- 英夫利西单抗谷浓度和阿达木单抗稳态水平为结局指标,使用ANSER英夫利西单抗和阿达木单抗检测法分析。
- 构建多变量线性混合效应模型评估妊娠期间英夫利西单抗和阿达木单抗药物水平,调整白蛋白、BMI和CRP临床协变量。
主要发现
- 15名女性(8例克罗恩病,7例溃疡性结肠炎)接受英夫利西单抗,10名女性共11次妊娠接受阿达木单抗治疗。
- 中位年龄29.6岁(IQR:27.6-31.2岁),中位疾病病程9.2年(IQR:3.16-15.0年)。
- 英夫利西单抗中位谷浓度在第1、2、3三个月分别为8.50 μg/mL(IQR:7.23-10.07 μg/mL)、10.31 μg/mL(IQR:7.66-15.63 μg/mL)和21.02 μg/mL(IQR:16.01-26.70 μg/mL)。
- 整个妊娠期间白蛋白和BMI有显著变化(P<0.05),但CRP无显著变化(P>0.05)。
- 调整白蛋白、BMI和CRP后,英夫利西单抗谷浓度在妊娠期间升高,每三个月增加4.2 μg/mL(P=0.02),而阿达木单抗药物水平保持稳定(P>0.05)。
临床怎么用
- 作者认为妊娠中期进行治疗药物监测可能有助于指导妊娠晚期给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary inflammatory bowel disease(IBD) pregnancy clinic on maintenance infliximab or adalimumab were recruited prospectively with serum bio-banking performed each trimester. Infliximab trough and adalimumab steady-state levels were the outcomes of interest and were analysed using the ANSER infliximab and adalimumab assays. Multivariate linear mixed-effects models were constructed to assess infliximab and adalimumab drug levels during pregnancy adjusting for the clinical covariates of albumin, BMI and CRP. RESULTS: Fifteen women (eight Crohn's disease, seven ulcerative colitis) received infliximab and 10 women with 11 pregnancies were treated with adalimumab. Median age was 29.6 years (IQR: 27.6-31.2 years). Median disease duration was 9.2 years (IQR: 3.16-15.0 years). Median trough infliximab concentrations were 8.50 μg/mL (IQR: 7.23-10.07 μg/mL), 10.31 μg/mL (IQR: 7.66-15.63 μg/mL) and 21.02 μg/mL (IQR: 16.01-26.70 μg/mL) at trimesters 1, 2 and 3 respectively. Significant changes in albumin and BMI (P < 0.05) but not CRP (P > 0.05) were documented throughout pregnancy. After adjusting for albumin, BMI and CRP, infliximab trough levels increased during pregnancy, by 4.2 μg/mL per trimester (P = 0.02), while adalimumab drug levels remained stable (P > 0.05). CONCLUSIONS: Infliximab levels rise during pregnancy, whereas adalimumab levels remain stable after accounting for changes in albumin, BMI and CRP. Therapeutic drug monitoring in the second trimester may be useful in guiding dosing in the third trimester.
引用
- Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28318043. doi:10.1111/apt.14040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。